Grant: Master's Award: Canada Graduate Research Scholarships - Master's program
University of Saskatchewan
$27,000.00
Assessing the Roles of Microglia in Treating a Monogenic Pediatric Disease
EF 2025-26
Résumé
X-linked adrenoleukodystrophy (X-ALD) is a rare but devastating pediatric neurometabolic disease that can rapidly progress after the onset of symptoms, often leading to irreversible neurological damage within months. X-ALD is caused by mutations in the ABCD1 gene. Allogeneic stem-cell transplantation (alloHSCT) is the only intervention utilized to slow this decline. However, alloHSCT carries significant long-term toxicity, requires long recovery periods, and its therapeutic mechanism is still not fully understood. Consensus in the field is that the transplanted cells repopulate the brain as microglia, the brain’s resident immune cells, helping restore function initially lost due to mutations. However, this model has never been validated. This uncertainty limits the design of safer, faster, and more targeted treatment. This project addresses that gap by investigating whether healthy microglia themselves are the central therapeutic agents responsible for the benefits observed after alloHSCT. We will examine how transplanted human microglia interact with pathological factors to determine whether replacing diseased microglia is sufficient to correct key aspects of X-ALD pathology. This work provides evidence which could possibly lead to the replacement of alloHSCT, thus avoiding its long-term ramifications. If microglial replacement is shown to be the primary catalyst of treatment, it would shift the therapeutic landscape for X-ALD from high-risk transplantation to targeted interventions designed to protect the brain during the narrow window available for effective treatment. Since many pediatric disorders are treated via alloHSCT, this framework could also guide the development of microglia-centred therapies for a wide range of pediatric diseases of neurological nature.
Programme
Master's Award: Canada Graduate Research Scholarships - Master's program
Bénéficiaire
Emplacement
Saskatchewan, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
572826
Name
Khunjush Kasra
Region
Saskatchewan
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Assessing the Roles of Microglia in Treating a Monogenic Pediatric Disease
Programtype2
Studentship Programs
Orgnameinp2
University of Saskatchewan
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Astrocytes; Induced Pluripotent Stem Cell; Ipsc; Microglia; Microglial Transplant; Neurons; Pluripotent Stem Cell; Stem Cell Transplant; X-Ald; X-Linked Adrenoleukodystrophy
Abstract
X-linked adrenoleukodystrophy (X-ALD) is a rare but devastating pediatric neurometabolic disease that can rapidly progress after the onset of symptoms, often leading to irreversible neurological damage within months. X-ALD is caused by mutations in the ABCD1 gene. Allogeneic stem-cell transplantation (alloHSCT) is the only intervention utilized to slow this decline. However, alloHSCT carries significant long-term toxicity, requires long recovery periods, and its therapeutic mechanism is still not fully understood. Consensus in the field is that the transplanted cells repopulate the brain as microglia, the brain’s resident immune cells, helping restore function initially lost due to mutations. However, this model has never been validated. This uncertainty limits the design of safer, faster, and more targeted treatment. This project addresses that gap by investigating whether healthy microglia themselves are the central therapeutic agents responsible for the benefits observed after alloHSCT. We will examine how transplanted human microglia interact with pathological factors to determine whether replacing diseased microglia is sufficient to correct key aspects of X-ALD pathology. This work provides evidence which could possibly lead to the replacement of alloHSCT, thus avoiding its long-term ramifications. If microglial replacement is shown to be the primary catalyst of treatment, it would shift the therapeutic landscape for X-ALD from high-risk transplantation to targeted interventions designed to protect the brain during the narrow window available for effective treatment. Since many pediatric disorders are treated via alloHSCT, this framework could also guide the development of microglia-centred therapies for a wide range of pediatric diseases of neurological nature.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Khunjush, Kasra
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~